Latest Quinazolines Stories
Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment BROOMFIELD, Colo., May 14 /PRNewswire/ -- Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on Monday, June 1st at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Western Branded Drug Sales Will Command 54 percent of the Market by 2013, According to a New Report from Decision Resources WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013.
Data Include First Presentation of Phase III Progression Free Survival Results for Pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- GlaxoSmithKline (GSK) Oncology announced that new clinical data from nine of its oncology molecules will be featured in various presentations at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando beginning May 29.
Current and Emerging Targeted Therapies Such As AstraZeneca's Iressa and Roche's Avastin Will Drive the Market From 2008 to 2013, According to a New Report from Decision Resources WALTHAM, Mass., May 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in China will more than double by 2013, growing from $307 million in 2008 to $648 million in 2013.
Test will help oncologists guide treatment of patients with non-small cell lung cancer BROOMFIELD, Colo., May 5 /PRNewswire/ -- Biodesix, Inc. today announces U.S.
An oral medication could help some patients with inflammatory breast cancer.
Finally some promising news about pancreatic cancer, one of the most fatal cancers, due to the difficulties of early detection and the lack of effective therapies
LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib).
A breast cancer chemotherapy drug shows benefits in fighting one type of breast cancer but not another type, U.S. researchers say.
A recent study suggests that advanced lung cancer patients might be able to avoid another chemotherapy treatment by taking a targeted pill treatment.